贝伐珠单抗致蛋白尿的文献病例分析

Case analysis of literature on bevacizumab-induced proteinuria

目的:了解贝伐珠单抗致蛋白尿的临床特点,为安全用药提供参考。方法:检索PubMed、OVid、Web of Science、Embase、Springer-link、Wiley Oline Library、CNKI、万方数据库和维普数据库等数据库,收集期刊文献中贝伐珠单抗致蛋白尿的病例进行分析。结果:共收集到贝伐珠单抗致蛋白尿患者12例,其中7例来自国内期刊,5例来自国外期刊。患者在出现蛋白尿后均停用贝伐珠单抗,最终患者蛋白尿症状及肾损伤都有所缓解。症状缓解的时间不同,最短为一个月。结论:贝伐单抗致蛋白尿出现的时间及严重程度在个体之间不一致,停药后均有所缓解,肾损害病例的肾功能均恢复正常,临床医师应了解贝伐珠单抗致蛋白尿的临床特点,使用抗VEGF药物前后应注意评估患者尿检及肾功能,加强用药监测,权衡用药的利与弊,及时发现和处理蛋白尿不良反应。

OBJECTIVE To understand the clinical features of bevacizumab-induced proteinuria and provide reference for safe drug use. METHODS Databases such as PubMed, OVid, Web of Science, Embase, Springer-link, Wiley Oline Library, CNKI, Wanfang Database, and VIP Database were searched to identify cases of bevacizumab-induced proteinuria in journal literature for analysis. RESULTS A total of 12 patients with bevacizumab-induced proteinuria were collected, of which 7 were from domestic journals and 5 were from foreign journals. Bevacizumab was discontinued after the onset of proteinuria, and both proteinuria and renal impairment resolved. The duration of symptom relief varied, with a minimum of one month. CONCLUSION The time and severity of bevacizumab-induced proteinuria were inconsistent among individuals and symptoms were relieved after discontinuation. Renal function in patients with renal impairment returned to norma. Clinicians should be aware of the clinical features of bevacizumab-induced proteinuria. Before and after the use of anti-VEGF drugs, attention should be paid to the assessment of urine and renal function in patients. In addition, we should strengthen drug monitoring, weigh the advantages and disadvantages of drug use as well as promptly detect and dealing with adverse effects of proteinuria.